Investment case
Werewolf Therapeutics, Inc.
HOWL · 4 developments mapped · last assessed 2026-08-21
Market Ontology has mapped 4 macro, policy, and market developments to Werewolf Therapeutics, Inc. since 2026-08-21. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for HOWL yet, so no modelled value is shown. The HOWL valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run HOWL on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Werewolf Therapeutics, Inc. to Acquire Ambros Therapeutics, Inc. ($500M)
Direct acquisition of another company, resulting in a change of corporate identity and ticker symbol, and potential dilution for existing shareholders.
· Moves future growth rates, synergy realization, cost of capital
What changed, by assumption
- 2026-08-21Werewolf Therapeutics, Inc. to Acquire Ambros Therapeutics, Inc. ($500M)
- 2026-08-21Werewolf Therapeutics, Inc. Files Business Combination Communication
- 2026-08-21Werewolf Therapeutics, Inc. to Acquire Ambros Therapeutics, Inc. ($548M)
- 2026-08-21Werewolf Therapeutics, Inc. Follow-On — $150M
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-21 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-08-21 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
| 2026-08-21 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-08-21 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-08-21 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
| 2026-07-31 | Valuation multiple | Bullish | Target re-rates to bid premium until close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-21 | Werewolf Therapeutics, Inc. to Acquire Ambros Therapeutics, Inc. ($500M) | mixed | 1-3m | 0.80 |
| 2026-08-21 | Werewolf Therapeutics, Inc. Files Business Combination Communication | mixed | 1-3m | 0.70 |
| 2026-08-21 | Werewolf Therapeutics, Inc. to Acquire Ambros Therapeutics, Inc. ($548M) | mixed | 1-3m | 0.70 |
| 2026-08-21 | Werewolf Therapeutics, Inc. Follow-On — $150M | mixed | 1-3m | 0.70 |